A Complicated Case of COVID-19-Induced Inferolateral Wall Myocardial Infarction Successfully Treated With Streptokinase

Taimoor Hussain 1, John Joyce 2, Salma Habib 3, Sohaib Toufiq 5, Sunny Ratnani 1, Sneha Puvvada 6

Abstract
The treatment of myocardial infarction (MI) in coronavirus disease 2019 (COVID-19)-positive patients is both controversial and challenging, particularly in a healthcare setup unable to fulfill COVID-19 protocols. In this report, we describe a case of a COVID-19-positive patient admitted with COVID-19 pneumonia treated symptomatically with a non-rebreathing mask, dexamethasone, remdesivir, and low-molecular-weight heparin (LMWH). On day two of the hospital stay, the patient developed inferolateral wall myocardial infarction (MI) without hemodynamic instability. He was treated successfully with thrombolytic (streptokinase) with no severe complications. However, his hospital stay was further complicated by decreasing oxygen saturation and rising inflammatory markers including procalcitonin and IL-6, suggesting superimposed bacterial infection. Thereafter, he was placed on BiPAP oxygen, and aggressive antibiotic therapy including tigecycline along with clindamycin and moxifloxacin was initiated. He showed gradual daily improvements and was discharged after a prolonged hospital stay. To decrease the exposure and spread of COVID-19 infection among the healthcare workers, when there is a deficiency in medical staff, and no negative-pressure catheterization laboratory, thrombolytic can be used for treatment in low-risk, hemodynamically stable MI during this pandemic. However, this needs further research.

Introduction
A number of complications of coronavirus disease 2019 (COVID-19) SARS-CoV-2 have been reported, including cardiac complications. According to a meta-analysis, "the most common complications were acute respiratory distress syndrome with 53.15%, while arrhythmia, acute cardiac injury, heart failure, and acute kidney injury were reported from 9% to 16%" [1]. According to a study, "cardiovascular complications also include myocarditis, acute myocardial infarction (MI), and venous thromboembolic events" [2]. In another large study of COVID-19 patients, "the fatality rate in those with coronary heart disease was 10.5% higher than the overall mortality rate of 2.3%" [3]. In addition, the social, economic, and psychological distress of the pandemic itself has resulted in stress-induced cardiomyopathy [4]. The treatment of COVID-19-induced MI is also a challenge given the ongoing pandemic and deficiency of medical staff, negative-pressure catheterization laboratory, personal protective equipment, and regular decontamination facility. We report a case of COVID-19 pneumonia in a 38-year-old diabetic and hypertensive male. He developed myocardial infarction subsequently on the second day of admission and was treated successfully by thrombolytic (streptokinase) without any severe complications. His hospital stay was further complicated by presumed superimposed bacterial infection and rising inflammatory markers, decreasing oxygen saturation. He was managed accordingly by an interdisciplinary team, and after a long 35-day hospital stay, he was discharged.

Case Presentation
A 38-year-old diabetic and hypertensive male came with complaints of shortness of breath associated with fever and cough for seven days. He was shifted to a tertiary care hospital from another center. He was suspected of bacterial and COVID-19 pneumonia. He was treated symptomatically with intravenous ceftriaxone, oxygen by simple mask, nebulized with ipratropium and beclomethasone, antihypertensives, and diabetes medications. Given the ongoing pandemic, a nasopharyngeal swab was taken, and he was tested for COVID-19 with reverse transcription-polymerase chain reaction (RT-PCR). His test was positive for COVID-19. He was thus shifted to the COVID-19 unit.

His initial laboratory tests were significant for leukocytosis; he has a WBC count of 20,900/µL, serum D-dimer levels of 305 ng/mL (normal range: <500 ng/mL), CRP of 75.09 mg/mL (reference range: 5 mg/L), and ferritin of 2000 ng/mL (reference range: 30–400 ng/mL). PT and aPTT, arterial blood gas analysis, and renal...
function tests were normal. He was vitally stable, except for oxygen saturation of 82%. The patient’s chest X-ray showed multifocal alveolar opacities, and he was diagnosed with multifocal pneumonia from COVID-19 (Figure 1). He was treated with oxygen using a non-breathing mask (NRM), intravenous dexamethasone, and remdesivir. Azithromycin was added to the treatment. He was also given S/C enoxaparin 40 mg once a day, vitamin C, and multivitamins.

Two days after admission, he complained of chest pain and increasing shortness of breath. Electrocardiogram (ECG) was performed, which showed ST-segment elevations II, III, AVf, V5, V6, and T-wave inversions (Figure 2). Cardiac troponin I (cTnI) was 0.7 ng/mL (reference range: <0.6 ng/mL). He was diagnosed with inferolateral wall myocardial infarction for which he was given dual antiplatelet therapy (DAPT), low-molecular-weight heparin (LMWH), and statin as per the acute coronary syndrome protocol. He was then given fibrinolytic therapy with 1.5 million unit streptokinase over 45 minutes with continuous monitoring of vitals. Chest pain resolved but caused hypotension for which he was given intravenous normal saline. ECG was repeated after 90 minutes, which showed the resolution of ST-segment elevations (Figure 3).
Thereafter, he was started on dual antiplatelet therapy along with lipid-lowering drugs. His antihypertensive and diabetes medications were continued. Brain natriuretic peptide (BNP) was tested for risk stratification in patients with acute coronary syndrome. His BNP level was 64.5 pg/mL (normal range: <125 pg/mL). On the second day post-MI, his oxygen saturation dropped despite being on NRM oxygen therapy. ECG and relevant baseline investigations were repeated and found normal. However, inflammatory markers showed a rising trend, including IL-6 of 150.6 pg/mL (reference range: <7 pg/mL), serum procollcalcinon of 0.67 ng/mL (reference range: <0.10 ng/mL), serum D-dimer levels of 2291 ng/mL (normal range: <500 ng/mL), CRP of 524.5 mg/L (reference range: <5 mg/L), and ferritin of 2000 ng/mL (reference range: 30-400 ng/mL). Therefore, a bacterial superinfection was suspected, and aggressive antibiotic therapy including tigecycline along with clindamycin and moxifloxacin was initiated. He was placed on BIPAP (20/10). He showed gradual improvement on a daily basis. His inflammatory markers showed a lowering trend. Chest X-ray showed resolution of opacities. He was shifted from BIPAP to simple mask oxygen. Finally, after 35 days of prolonged hospitalization, he was discharged. Currently, on follow-up visits, the patient was asymptomatic, had no complications from the dual antiplatelet therapy, and was advised coronary angiogram.

Discussion

As the pandemic continues, a number of COVID-19 complications are reported, and therapeutic concepts have evolved. Acute myocardial injury in COVID-19 is also being reported increasingly for which different mechanisms are proposed. According to a case series of 5700 patients, a high number of COVID-19 patients have cardiovascular risk factors including hypertension (56.6%), obesity (41.7%), and diabetes (33.8%) [5]. The proposed mechanism of COVID-19-induced MI is summarized as follows. The hypoxic state and systemic inflammatory response due to the cytokine storm cause endothelial damage and cardiac ischemia; activated macrophages secrete collagenases that degrade collagen, a major constituent of the fibrous cap on atherosclerotic plaques, destabilizing the atherosclerotic plaque, and tissue factor that is a potent pro-coagulant leads to a state of hypercoagulability and thromboembolic events [6-9]. Bioinformatics studies suggested that some binding proteins and viral envelope glycoproteins may bind to both porphyrin and the β-chain of hemoglobin, decreasing available serum hemoglobin, consequently leading to hypoxemia and type 2 AMI, and hypoxemia, with pulmonary and cardiac consequences [6,10]. In addition, angiotensin-converting enzyme 2 (ACE-2) signaling pathways are damaged from direct damage to ACE receptors on myocytes [11].

According to a study in 201 COVID-19 patients with myocardial injury, elevation in CKMB and troponin I levels was found in all of them; 45.7% presented with new electrocardiography (ECG) changes, 36.3% had ST depression, and 18.7% of the patients had abnormal echocardiography findings, and right ventricular dilatation and dysfunction were commonly seen in the critical group patients [12]. cTnI, cardiac troponin (cTnT), and BNP have shown remarkable potential in predicting COVID-19 outcomes and deteriorating health. Those with higher cTnI levels have statistically significantly higher mortality as compared to others with normal levels [13]. Therefore, detecting elevated serum cTnT or cTnI levels on admission as a routine procedure has immense value in reducing mortality.

The treatment of COVID-19–induced myocardial infarction is controversial. In patients diagnosed with an ST-elevation myocardial infarction (STEMI) and COVID-19, the American College of Cardiology (ACC) recommends "that percutaneous coronary intervention is the treatment of choice; however, fibrinolysis can be considered in those with 'low-risk STEMI,' defined by inferior STEMI with no right ventricular involvement or lateral AMI without hemodynamic compromise" [14]. If an unconfirmed COVID-19 patient develops non–ST-elevation MI (NSTEMI), it is better to do a diagnostic test before catheterization; the ACC further mentions that "conservative therapy may be sufficient in properly triaged patients with confirmed COVID-19. Hemodynamically unstable NSTEMI patients should be managed on the lines of those with STEMI" [14]. However, in many setups, the requirements for performing PCI in COVID-19 patients cannot be fulfilled. These requirements include wearing personal protective equipment, air-purifying respirators, and decontaminated and negative-pressure catheterization laboratory. Our patient had clinical symptoms, raised troponin, and hemodynamically stable but inferior STEMI with lateral wall involvement. We
successfully treated our patient with streptokinase to decrease the chances of spreading infection in the hospital and due to unpreparedness to fulfill the COVID-19 protocol.

**Conclusions**

Hypercoagulability and thromboembolic events in COVID-19 lead to pulmonary and cardiac complications. cTnI, cTnT, and BNP can be used to predict COVID-19 outcomes and deteriorating health. Those with higher cTnI levels have statistically significantly higher mortality as compared to others with normal levels. In many setups, the requirements for performing PCI in COVID-19 patients cannot be fulfilled. In such situations, streptokinase can be considered to curb the spread of infection in the hospital and when unprepared to fulfill the COVID-19 protocol.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Vakili K, Fathi M, Pezeshgi A, Mohamadkhani A, Hajiesmaeili M, Rezaei-Tavirani M, Sayehmiri F: Critical complications of COVID-19: a descriptive meta-analysis study. Rev Cardiovasc Med. 2020, 21:453-42. 10.51085/r.cm.2020.05.129
2. Long B, Brady WJ, Koyfman A, Gottlieb M: Cardiovascular complications in COVID-19. Am J Emerg Med. 2020, 38:1504-7. 10.1016/j.ajem.2020.04.048
3. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention: [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020, 41:145-51. 10.3760/cma.j.issn.0254-6450.2020.02.005
4. Desai HD, Sharma K, Judeja DM, Desai HM, Moliva P: COVID-19 pandemic induced stress cardiomyopathy: a literature review. Int J Cardiol Heart Vasc. 2020, 31:100628. 10.1016/j.ijcha.2020.100628
5. Richardson S, Hirsch JS, Narasimhan M, et al.: Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020, 325:2052-9. 10.1001/jama.2020.6775
6. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction: Fourth universal definition of myocardial infarction (2018). Glob Heart. 2018, 13:505-38. 10.1016/j.gheart.2018.08.004
7. Klok FA, Kruip MJ, van der Meer NJ, et al.: Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020, 191:145-7. 10.1016/j.thromres.2020.04.015
8. Ye Q, Wang B, Mao I: The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. J Infect. 2020, 80:607-13. 10.1016/j.jinf.2020.05.037
9. Libby P, Tabas I, Fredman G, Fisher EA: Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014, 114:1867-79. 10.1161/CIRCRESAHA.114.302699
10. Cavezzzi A, Troiani E, Corrao S: COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin Pract. 2020, 10:1271. 10.4081/cp.2020.1271
11. Chen L, Li X, Chen M, Feng Y, Xiong C: The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020, 116:1097-100. 10.1093/cvr/cvaa078
12. Liaquat A, Ali-Khan RS, Atad M, Rafique Z: Evaluation of myocardial injury patterns and ST changes among critical and non-critical patients with coronavirus-19 disease. Sci Rep. 2021, 11:4828. 10.1038/s41598-021-84467-4
13. Aboughdir M, Kirwin T, Abdul Khader A, Wang B: Prognostic value of cardiovascular biomarkers in COVID-19: a review. Viruses. 2020, 12:527. 10.3390/v12050527
14. Welt FG, Shah PB, Aronov HD, et al.: Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from the ACC’s interventional council and SCAI. J Am Coll Cardiol. 2020, 75:2372-5. 10.1016/j.jacc.2020.05.021

2021 Hussain et al. Cureus 13(12): e20348. DOI 10.7759/cureus.20348